Lupin Gets US FDA Approval for Pitolisant Tablets in 4.45 mg and 17.8 mg Strengths
Lupin Limited has announced that it has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets, 4.45 mg and 17.8 mg.
The announcement was made by Lupin on August 17, 2026, marking another U.S. regulatory approval for the Mumbai-based pharmaceutical company.
Lupin Receives Final US FDA Approval
According to the company, the U.S. FDA has granted final approval for Lupin’s Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
The approved products have been determined to be bioequivalent to Wakix® for the indications included in the approved labeling.
Pitolisant is therefore another product that Lupin can add to its portfolio of approved pharmaceutical products for the U.S. market.
What Is the Pitolisant Approval?
The approval relates to Lupin’s Abbreviated New Drug Application (ANDA).
The U.S. FDA approved:
- Pitolisant Tablets 4.45 mg
- Pitolisant Tablets 17.8 mg
The products are approved as bioequivalent to Wakix®, subject to the indications contained in the approved labeling.
The company announcement does not provide additional details on the expected launch date, commercial opportunity, or potential revenue contribution from the product.
Why the U.S. FDA Approval Matters for Lupin
The U.S. is an important pharmaceutical market for Lupin, and regulatory approvals provide the company with opportunities to expand its portfolio of generic and complex pharmaceutical products.
The latest Pitolisant approval adds another product to Lupin’s U.S. portfolio and highlights the company’s ongoing focus on developing and commercialising pharmaceutical products across international markets.
However, the company has not disclosed specific sales guidance or revenue estimates related to this approval in the announcement.
Lupin’s Global Pharmaceutical Business
Lupin is a global pharmaceutical company headquartered in Mumbai, India, with products distributed across more than 100 markets, according to the company.
Its portfolio includes:
- Branded formulations
- Generic formulations
- Complex generics
- Biotechnology products
- Active pharmaceutical ingredients (APIs)
The company has a presence across several therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health.
Lupin operates 15 manufacturing sites and six research centres globally, supported by a workforce of more than 26,000 professionals, according to the company.
Lupin Stock: Key Point for Investors
For investors tracking Lupin shares, the Pitolisant approval is a positive regulatory development, particularly because it expands the company’s approved U.S. product portfolio.
The key factors to watch going forward will be the commercial launch, market opportunity, competition, pricing and eventual contribution to Lupin’s U.S. business.
At present, Lupin’s August 17 announcement confirms the final U.S. FDA approval, but does not provide a specific launch date or financial guidance for Pitolisant.
About Lupin Limited
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India. The company operates across branded and generic formulations, complex generics, biotechnology products and APIs.
Its products are distributed in more than 100 markets worldwide.
NSE: LUPIN
BSE: 500257
Announcement Date: August 17, 2026
Approval: U.S. FDA Final Approval
Product: Pitolisant Tablets
Strengths: 4.45 mg and 17.8 mg
Reference Product: Wakix®
This article is based on Lupin Limited’s press release dated August 17, 2026. The company announcement confirms the U.S. FDA approval but does not provide specific revenue guidance, launch timing, or market-share estimates for Pitolisant.